{"protocolSection":{"identificationModule":{"nctId":"NCT05220449","orgStudyIdInfo":{"id":"2017-01761"},"organization":{"fullName":"Ecole Polytechnique Fédérale de Lausanne","class":"OTHER"},"briefTitle":"Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery","officialTitle":"Individualized Brain Stimulation to Improve Functional Rehabilitation in Two Models of Sensorimotor Disorders: Stroke and Parkinson's Disease","acronym":"R4V"},"statusModule":{"statusVerifiedDate":"2022-01","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-09-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-08-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-11-30","studyFirstSubmitQcDate":"2022-01-27","studyFirstPostDateStruct":{"date":"2022-02-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-01-27","lastUpdatePostDateStruct":{"date":"2022-02-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Estelle Raffin","investigatorTitle":"Teaching and Research Associate","investigatorAffiliation":"Ecole Polytechnique Fédérale de Lausanne"},"leadSponsor":{"name":"Ecole Polytechnique Fédérale de Lausanne","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This project assesses the effect of bifocal cross-frequency transcranial alternating current stimulation (tACS) combined with visual training to improve visual recovery and orchestrated oscillatory activity in stroke patients suffering from visual field defects."},"conditionsModule":{"conditions":["Visual Impairment","Stroke","Parkinson Disease"],"keywords":["Stroke","Visual field","Oscillations","tACS","Parkinson's Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"Double (Participant \\& Investigator)","whoMasked":["INVESTIGATOR"]}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cf-tACS (V1-Alpha_V5-Gamma)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Cross-frequency dual-site tACS"]},{"label":"Cf-tACS (V1-Gamma_V5-Alpha)","type":"EXPERIMENTAL","interventionNames":["Other: Cross-frequency dual-site tACS"]}],"interventions":[{"type":"OTHER","name":"Cross-frequency dual-site tACS","description":"Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)","armGroupLabels":["Cf-tACS (V1-Alpha_V5-Gamma)","Cf-tACS (V1-Gamma_V5-Alpha)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Changes in visual field functions","description":"Comparison of the systematic measurement of the visual field using Humphrey perimetry","timeFrame":"Measured at baseline (i.e. before the first day of intervention), and post intervention (i.e., after the last day of intervention)"}],"secondaryOutcomes":[{"measure":"Changes in motion discrimination and integration performances","description":"Comparison of the motion coherence threshold extracted from a two forced-choice direction discrimination task","timeFrame":"Measured at baseline (i.e. before the first day of intervention), and post intervention (i.e., after the last day of intervention)"},{"measure":"Changes in inter-areal cross-frequency interaction","description":"Comparison of the inter-areal Alpha-Gamma coupling using electroencephalography recordings","timeFrame":"Measured at baseline (i.e. before the first day of intervention), and post intervention (i.e., after the last day of intervention)"},{"measure":"Changes in visual tracts integrity","description":"Comparison of the diffusion weigted imaging-based tractography of the main visual tracts","timeFrame":"Measured at baseline (i.e. before the first day of intervention), and post intervention (i.e., after the last day of intervention)"},{"measure":"Changes in functional connectivity within the broad visual network","description":"Functional MRI based connectivity analyses using DCM or graph theory will perfomed","timeFrame":"Measured at baseline (i.e. before the first day of intervention), and post intervention (i.e., after the last day of intervention)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. the patient can consent for themselves;\n2. age 18+ years old;\n3. at least 7 days since diagnosis \"stroke\".\n4. Patients should demonstrate a clear deficit in either simple or complex visual perception in portions of their visual field\n\nExclusion Criteria:\n\n1. Diminished capacity to consent;\n2. Pregnancy\n3. Known or suspected non-compliance, drug or alcohol abuse\n4. Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant,\n5. Non-compliance to the instructions of the experimenter or an inappropriate behavior hindering the normal progress of the experiment.\n6. Previous enrolment into the current study\n7. Exclusion criteria of MRI, tACS, TMS\n8. Use of psychoactive medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Estelle Raffin, PhD","role":"CONTACT","phone":"0216955185","phoneExt":"+41","email":"estelle.raffin@epfl.ch"},{"name":"Friedhelm Hummel, Professor","role":"CONTACT","email":"friedhelm.hummel@epfl.ch"}],"locations":[{"facility":"Campus Biotech, EPFL","status":"RECRUITING","city":"Geneva","zip":"1201","country":"Switzerland","contacts":[{"name":"Pauline Stehli, Msc","role":"CONTACT"}],"geoPoint":{"lat":46.20222,"lon":6.14569}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000010300","term":"Parkinson Disease"},{"id":"D000014786","term":"Vision Disorders"},{"id":"D000015354","term":"Vision, Low"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020734","term":"Parkinsonian Disorders"},{"id":"D000001480","term":"Basal Ganglia Diseases"},{"id":"D000009069","term":"Movement Disorders"},{"id":"D000080874","term":"Synucleinopathies"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000012678","term":"Sensation Disorders"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000005128","term":"Eye Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M12903","name":"Parkinson Disease","asFound":"Parkinson's Disease","relevance":"HIGH"},{"id":"M17732","name":"Vision, Low","asFound":"Visual Impairment","relevance":"HIGH"},{"id":"M17220","name":"Vision Disorders","asFound":"Visual Impairment","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M22184","name":"Parkinsonian Disorders","relevance":"LOW"},{"id":"M25293","name":"Ganglion Cysts","relevance":"LOW"},{"id":"M16048","name":"Synovial Cyst","relevance":"LOW"},{"id":"M4464","name":"Basal Ganglia Diseases","relevance":"LOW"},{"id":"M11719","name":"Movement Disorders","relevance":"LOW"},{"id":"M2217","name":"Synucleinopathies","relevance":"LOW"},{"id":"M21248","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M15180","name":"Sensation Disorders","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M7961","name":"Eye Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC11","name":"Eye Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M16664","name":"Triamcinolone","relevance":"LOW"},{"id":"M16665","name":"Triamcinolone Acetonide","relevance":"LOW"},{"id":"M237937","name":"Triamcinolone hexacetonide","relevance":"LOW"},{"id":"M209531","name":"Triamcinolone diacetate","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}